Please login to the form below

migalastat

This page shows the latest migalastat news and features for those working in and with pharma, biotech and healthcare.

Galafold (migalastat) is an oral medication for the treatment of Fabry disease, a rare lysosomal metabolic storage condition.

Daily Brief: Orchard raises $150m, Astellas swoops for early-stage gene company, Amicus gets FDA Fabry approval

Galafold (migalastat) will be the first new Fabry treatment on the US market in more than 15 years, and will compete with Sanofi’s infusion-based Fabrazyme treatment.
Amicus Therapeutics launches Fabry treatment Galafold in Italy

Follows publication of Ministry of Health's reimbursement guidelines. US biotech Amicus Therapeutics has launched its new Fabry disease treatment Galafold (migalastat) in Italy after winning reimbursement coverage.
Amicus gets NICE green light for Fabry drug

disorder. The UK's cost-effectiveness regulator has published final guidance endorsing the use of Galafold (migalastat) for Fabry, an inherited lysosomal storage disease caused by deficiency in the enzyme ... At one point migalastat was licensed to
SMC approves Opdivo combo as first-line skin cancer treatment

Amicus Therapeutics' Galafold (migalastat) has also received the go-ahead, and has been sanctioned by the SMC for the treatment of adults with Fabry disease, an incurable inherited genetic disorder.
NICE backs Amicus Therapeutics’ Galafold

Recommends oral alternative for treating Fabry disease. The UK's NICE has recommended the use of Galafold (migalastat) on the NHS for the treatment of Fabry disease in draft Highly Specialised

More from news
Approximately 2 fully matching, plus 5 partially matching documents found.

Pharma deals in August 2015

Acquisition of remaining rights. 1034. Scioderm. Amicus. Galafold [migalastat] for Fabry's disease.
Pharma deals during November 2013

Firstly, GSK decided to return rights to the experimental Fabry disease drug migalastat, noting that support would continue through GSK's equity investment of $3m.

More from intelligence
Approximately 0 fully matching, plus 2 partially matching documents found.

Market Access Director, six figure base salary and £5K joining b...: Highly competitive salary

Principal Medical Writer/ Scientific Lead, Medcomms, £5K joining...: Highly competitive salary

Exciting Medical Writer Career Opportunity for Postdoc, Medcomms: Highly competitive salary

Add my company

HME are an innovative and technology enabled agency offering our clients over 35+ years of knowledge and expertise in delivering...

Virtual Steering Committee & Peer Influence Program: In this customer story, we describe the methodology and results of our client’s ongoing Virtual Steering Committee & Peer Influence program....
Meeting healthcare’s rising challenges: The journey to discover novel therapies through digital innovation and ensure scientific advances achieve their potential...
Report gives insights to address gaps in HCP engagement: How does Pharma-HCP engagement need to evolve in today's digital landscape?...

Email:
Password: